Abstract-The invention of atomic force microscopy (AFM) provides new technology for measuring the molecular specific binding forces. With the use of AFM single-molecule force spectroscopy (SMFS), the CD20-rituximab binding forces were measured on purified CD20 proteins (CD20 segment protein and CD20 full-length protein) and on Burkitt's lymphoma Raji cells, respectively. With AFM probe functionalization technology, rituximabs were linked onto AFM tips. With substrate functionalization technology, purified CD20 segment proteins and CD20 full-length proteins were attached onto mica. Lymphoma Raji cells were immobilized onto glass substrate with electrostatic adsorption and chemical fixation. The differences of measuring the binding forces on purified proteins and on cells were analyzed. The experimental results indicate that the binding force between CD20 segment protein and rituximab were markedly larger than that of CD20 full-length protein and CD20 protein on lymphoma cells, providing an effective method for investigating the rituximab's mechanism.
I. INTRODUCTION
HE invention of atomic force microscopy (AFM) [1] opens the possibility for investigating the topography structure and molecular specific recognition interactions of individual live cells and molecules, revolutionizing the research methods of various fields in life sciences. The resolution of light microscopy is limited to the wavelength of the light source and therefore information on the nanometer scale is not accessible, while electron microscopy requires the vacuum conditions and therefore live samples can not be investigated [2] . Compared with light microscopy and electron microscopy, AFM has sub-nanometer resolution [3] , can work in various conditions, such as air, liquids, and vacuum, can visualize live cells and native biomolecules without the need for staining or fixation [4] . These particular advantages make AFM widely applied in life sciences and researches of individual cells/molecules based on AFM have become the frontiers and hot topics in life sciences [5] [6] [7] .
With the advancements in the past two decades, AFM has evolved into a multifunctional tool [4] . By treating the AFM tip and substrates chemically, the protein-protein specific binding forces can be measured at force curve mode, which is called single-molecule force spectroscopy (SMFS) [8] . In SMFS, ligands/antibodies are linked onto AFM tips, and receptors/antigens are bound onto the substrate. Using the functionalized tip to obtain force curves on the protein-coated substrate, the binding forces of antibody-antigen/ receptor-ligand can be measured. SMFS was first performed in the mid 1990s. In 1994, Florin [9] et al measured the binding force of biotin-avidin on biotinylated agarose bead, by linking avidin to AFM tip; in 1996, Hinterdoefer [10] et al measured the binding forces of human serum albumin(HSA) and anti-HSA, by linking anti-HSA on to AFM tip with polyethylene glycol(PEG) linker molecules and linking HSA onto mica surface. Besides measuring the molecular forces on protein-coated substrate, SMFS can also measure the molecular forces on cell surface. In 2006, Puntheeranurak [11] et al measured the specific binding forces of Na + -glucose co-transporter(SGLT1) and its antibodies on Chinese hamster ovary(CHO) cells; in 2009, Shi [12] et al investigated the interaction forces of Heregulin and HER3 on HEK(human embryonic kidney) 293 cells.
Clinical applications of rituximab(anti-CD20 monoclonal antibody) in the past decade have indicated the markedly efficacy difference for different B-cell non-Hodgkin's lymphoma patients [13] . The target of rituximab is the CD20 antigen which is a tetra-spanning membrane protein and is expressed on mature B cells and most B-cell lymphomas [14] . After binding with the CD20 on the cell surface, rituximab induces the lysis of the targeted cell by antibody-dependent cellular cytotoxicity(ADCC), complement-dependent cytotoxicity(CDC), and programmed cell death(PCD) [15] . Rituximab achieved unprecedented success, and particularly in combination with chemotherapy, significantly improved the survival statistics of lymphoma patients [16] . However, owing to the various efficacies for different patients, the urgent need is to enhance its efficacy [13] . A better understanding of rituximab-medicated killing mechanisms should make it possible to develop new and more effectively therapeutic agents [17] . In this paper, with the use of SMFS, the specific CD20-rituximab recognition interactions were investigated, and the binding forces of rituximab to CD20 segment protein, CD20 full-length protein, and CD20 proteins on lymphoma cell surface were measured respectively, providing an effective method for investigating 
II. PRINCIPLE
The principle of measuring the CD20-rituximab binding forces was shown in Figure 1 . Rituximab was linked onto the AFM tip through the PEG linker molecule. When measuring the binding force between purified CD20 proteins and rituximab, CD20 proteins were attached onto mica substrate (Figure 1(a) ). When measuring the binding force between CD20 proteins on lymphoma cells and rituximab, lymphoma cells were immobilized onto glass surface by electrostatic adsorption and chemical fixation (Figure 1(b) ). At force curve mode, the probe approached gradually and contacted the substrate/cell, making the rituximab molecules on the tip bind the CD20 molecules on the substrate/cell to form CD20-rituximab complexes. Then the probe retracted from the substrate/cell, and when the exerted force of the probe was equal to the CD20-rituximab binding force, the CD20-rituximab complexes dissociated. By recording the displacement of the piezotube and the deflection of the probe cantilever during the approach-retract cycle, force-distance curves were constructed ( Figure 1(c) ). Each force curve contains two portions, approach curve and retract curve. If the CD20-rituximab binding events occurred during the approach process, then there was an abrupt peak in the retract portion of the force curve. The abrupt peak corresponded to the dissociation process of CD20-rituximab complexes. By analyzing the force curves, single CD20-rituximab binding forces can be calculated.
III. MATERIALS AND METHODS

A Materials
Rituximabs(10mg/ml) were obtained from Chinese affiliated hospital of military medical academy of sciences. N-hydroxysuccinimide-polyethylene glycol-Maleimide (NHS-PEG-MAL, MW2000) was purchased from JenKem Company (China). Some of the functionalization reagents were purchased from Sigma-Aldrich Company (USA), including aminopropyltriethoxysilane (APTES), NNdiisopropylethylamine, triethylamine, and phosphate buffered saline (PBS). The other functionalization reagents were purchased from J&K Company (China), including hydroxylamine, chloroform, dimethyl sulfoxide(DMSO), and N-Succinimidyl 3-(Acetylthio) propionate (SATP). CD20 segment protein, poly-L-lysine, and glutaraldehyde were purchased from Solarbio Company (China). CD20 full-length protein was purchased from Huaruikang Company (China). Milli-Q ultra-pure water (18.2MΩ.cm) was used for all experiments.
B Protein immobilization
CD20 proteins were attached onto freshly cleaved mica (1cm×1cm squares) according to the established procedure [18] . ① Purge a glass desiccator with argon for 2 minutes. ② Pipette 30 μL APTES into a small petri dish and 10 μL NN-diisopropylethylamine into another small petri dish. ③ After putting the freshly cleaved mica and the two petri dishes into the glass desiccator, purge the desiccator with argon for 2 minutes and seal for 0.5-2 hours. ④ Pipette 200 μL glutaraldehyde solutions onto the mica and incubated for 10 minutes. ⑤ Rinse the mica with Milli-Q ultra-pure water and then add 100 μL CD20 protein solutions onto the mica and incubated for 30 minutes. ⑥ Rinse the mica with Milli-Q ultra-pure water again and put the mica into a petri dish with PBS for being probed by AFM. The Burkitt's lymphoma Raji cells were cultured at 37℃ (5%CO 2 ) in RPMI-1640 culture medium containing 10% fetal bovine serum. Raji cells were attached on the glass slide by poly-L-lysine's electrostatic adsorption and glutaraldehyde's chemical fixation. ①Cover the glass slide with poly-L-lysine and store the slide at room temperature overnight. ②Harvest cells by centrifuging at the speed of 1000r/min. ③Drop the cell suspension onto the glass slide. ④After 30 minutes, fix the cells with 0.25% glutaraldehyde for 15 minutes and then put the slide onto a petri dish with PBS for AFM experiments.
C Probe functionalization
The heterobifunctional linker NHS-PEG-MAL was used to tether rituximabs onto the AFM styluses. This linker has a NHS ester on one end and a MAL ester on the other. The stylus functionalization process followed an established procedure [19] . ① Use 30μL APTES and 10μL NN-diisopropylethylamine to coat the AFM stylus with amino groups (NH 2 
D AFM Measurements
AFM imaging and measurements were performed using a Dimension 3100 AFM (Veeco company) with silicon nitride probes(0.06N/m). The spring constant was calibrated by a Thermal Tune Adapter (Veeco Company). Experiments were performed in PBS at room temperature. At force curve mode, with functionalized probes, 4 measurements were performed and ~500 force curves were obtained on CD20 segment protein, CD20 full-length protein, and Raji cells respectively. Blocking experiments [20] were used to verify the specific CD20-rituximab binding forces. Free rituximabs were added to mask the CD20 molecules on the substrate/cell, and about 30 minutes later, force curves were obtained again.
E Poisson analysis
In the process of obtaining force curves, several CD20-rituximab complexes might form. Possion analysis [21] was used to calculate the single CD20-rituximab binding forces. The formula of Possion analysis is as followed:
, μ are variance and mean in one measurement, and F is the binding force. If several measurements at the same loading rate are performed, variance against mean can be plotted and the single CD20-rituximab binding force is equal to the slope of the fit line. Figure 2 represents the results of measuring the binding forces between CD20 segment protein and rituximab. After treating the mica with APTES and glutaraldehyde, the exposed aldehyde can react with lysine residues [18] . Both of the CD20 segment protein and full-length protein contain lysine residues and therefore they were cross-linked onto the mica. A typical force curve obtained on mica covered with CD20 segment proteins with rituximab-conjugated probes was shown in Figure 2(a) . The black line indicates the approach process, and the red line indicates the retract process. We can see that there was an abrupt peak on the retract curve. After adding free rituximabs, force curves were obtained again and there were no peaks on the retract curve, as was shown in Figure 2(b) . This verified that the peak in Figure 2(a) corresponded to the specific binding between CD20 segment protein on the mica and the rituximab on the AFM tip. After computing the binding forces for each force curve obtained on the mica, the histogram of the binding forces was constructed (Figure 2(c) ). Gaussian fit of the histogram indicated that the binding force was 276±125pN. For the four measurements, mean and variance was calculated. The mean was 0.3753, 0.3257, 0.2865, 0.2945, respectively, and the variance was 0.0242, 0.0118, 0.0092, 0.0039, respectively. From the plot of variance against mean, we can see that the slope of the fit line indicated that the individual binding force was 200pN (Figure 2(d) ). Figure 3 represents the results of measuring the binding forces between CD20 full-length protein and rituximab. A typical force curve obtained on mica covered with CD20 full-length proteins with rituximab-conjugated probes was shown in Figure 3(a) . We can see that there was an abrupt peak on the retract curve, and after adding free rituximab, the peak disappeared (Figure 3(b) ). This verified that the peak in Figure 3 (a) corresponded to the specific binding between CD20 full-length protein on the mica and the rituximab on the AFM tip. After computing the binding forces for each force curve obtained on the full-length proteins, the histogram of the binding forces was constructed (Figure 3(c) ) and Gaussian fit of the histogram indicated that the binding force was 182±69pN. For the four measurements, the mean was 0.2053, 0.1814, 0.2035, 0.2353, respectively, and the variance was 0.0063, 0.0024, 0.0023, 0.0087, respectively. The slope of the fit line of the plot of variance against mean indicated that the individual binding force was 121pN ( Figure  3(d) ). Figure 4 shows the results of measuring the binding forces between CD20 proteins on the lymphoma cell surface and rituximab. A typical force curve obtained on lymphoma cell surface with rituximab-conjugated probes was shown in Figure 4 (a). We can see that there was an abrupt peak on the retract curve, and after adding free rituximab, the peak disappeared (Figure 4(b) ). This verified the CD20-rituximab specific binding interactions. From Figure 4 (b), we can see that there was a small peak on the retract curve and the magnitude of the peak was much smaller than that in Figure  4 (a). This may due to the unspecific interactions in the solution. Figure 4(c) was the histogram of the binding forces. Gaussian fit indicated that the binding forces were 165± 47pN and 355±291pN. For the four measurements, the mean was 0.2567, 0.3487, 0.6193, 0.8628, respectively, and the variance was 0.0038, 0.0059, 0.041, 0.0472, respectively.
IV. RESULTS AND DISCUSSION
The slope of the fit line of the plot of variance against mean indicated that the individual binding force was 79pN ( Figure  4(d) ). Analyzing the measuring results of the CD20-rituximab binding forces on CD20 segment protein, CD20 full-length protein, and CD20 protein on lymphoma cell surface, from the histograms we can see that the binding force of the CD20 segment protein was 276±125pN, the binding force of the CD20 full-length protein was 182±69pN, and the binding forces of the CD20 protein on lymphoma cell surface were 165±47pN and 355±291pN. We can see that the Gaussian fit of the histogram measured on lymphoma cells was bimodal distribution, while the histograms measured on CD20 segment proteins and full-length proteins were unimodal distribution. This may due to the surface topography of the cell. The cell surface was corrugated and rough, and CD20 proteins were distributed on the corrugated cell surface, unlike the CD20 proteins on the flat mica surfaces. And this may result in the bimodal distribution of the binding forces. Additionally, the first distribution peak value (165±47pN) was close to the peak value of CD20 full-length protein (182±69pN), while it was significantly different to the distribution peak value of CD20 segment protein. In the process of measuring the binding forces, several CD20-rituximab complexes might form and after Poisson analysis, the individual CD20-rituximab binding forces of CD20 segment protein, CD20 full-length protein, and CD20 protein on lymphoma cell surface were 200pN, 121pN, and 79pN. We can see that the binding force of CD20 segment protein was the largest, and the binding force of the CD20 full-length protein was relatively close to that of CD20 protein on lymphoma cell surface. Binder et al [22] used phage display peptide libraries to conclude that the epitope recognized by rituximab is formed by the peptide (170) ANPS (173) and (182) YCYSI (186). The CD20 segment protein was synthetic peptide with the amino acid sequence SSQPKNEEDIY, while CD20 full-length protein was recombinant protein. We can see that the amino acid sequence of CD20 segment protein was different from the epitope area's amino acid sequence of CD20 full-length protein and this may result in the difference of CD20-rituximab binding forces. Additionally, CD20 proteins expressed on prokaryotic cells in vitro do not completely correspond to the natural human CD20 proteins in vivo. For mammalian proteins, a mammalian expression system is likely to give the best results in terms of structure and functionality of the protein [23] . The tremendous difference between in vitro and in vivo can result in the difference to the proteins. And these differences may result in the variable strength of CD20-rituximab binding forces. These results indicate that one possible reason of the variable rituximab's efficacies for lymphoma different patients is that the variant CD20 proteins on the lymphoma B cell surface results in the different CD20-rituximab binding forces and therefore influences the rituximab's efficacies. 
V. CONCLUSION
In the Rituximab targeted therapy of B-cell non-Hodgkin's lymphoma, more potent targeted drug was strongly due to the significantly different efficacies. AFM single-molecule force spectroscopy provides new methods for investigating the molecular specific interactions, and new knowledge about the molecular interactions at individual cell/molecule level is acquired. With AFM single-molecule force spectroscopy, the binding forces of rituximab to CD20 segment protein, CD20 full-length protein, and CD20 protein on lymphoma cell were measured, the difference of the three binding forces were analyzed. The experimental results indicated that the binding force between CD20 segment protein and rituximab was the largest (200pN), and the binding force of CD20 full-length protein was close to that of CD20 protein on lymphoma cell surface. These results laid the foundation for investigating the molecular mechanism of rituximab's efficacy, and might provide some key technologies for the development of next monoclonal antibody drug.
